Immunomodulatory Effect of Multipotent Stromal Cells



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Multipotent stromal (stem) cells are currently the subject of extensive research. Initially, special attention was given to their reparative properties; however, in recent years, the focus switched toward their immunomodulatory effects. Multipotent cells inhibit T cell proliferation (directly and via exosomes), suppress proinflammatory cytokine production, and activate anti-inflammatory cytokine synthesis. Owing to these effects, cell technologies are currently used in the treatment of Huntington disease, multiple sclerosis, autoimmune encephalomyelitis, scleroderma, systemic lupus erythematosus, rheumatoid arthritis, myasthenia gravis, and other disorders. Furthermore, multipotent stromal cells have demonstrated efficacy in acute respiratory distress syndrome models, supporting their potential use in the treatment of COVID-19 complications. They interact with target cells via both paracrine signaling and direct cell–cell interactions. However, multipotent cell-driven immunoregulation and immunosuppression mechanisms are still poorly understood. The use of multipotent cells is highly dependent on the cell source and their functions in vivo; moreover, functional capabilities of stem cells are known to decline with age. It is also essential to consider potential complications of immunomodulatory effects of multipotent stromal cells, including long-term, severe immunosuppression, which may result in prolonged inflammation in infections and facilitate the progression of malignant neoplasms. For the effective use of multipotent cells, changes in gene expression induced by cell culture and various disorders must be taken into account. Further research is warranted into the mechanisms behind the immunomodulatory effect of multipotent stromal cells, as well as indications and contraindications for cell therapy in humans and animals. Moreover, it will be beneficial to investigate ways to control the functions of stem cells in various microenvironments.

About the authors

Igor V. Maiborodin

Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences; Novosibirskii mediko-stomatologicheskii institut Dentmaster

Author for correspondence.
Email: imai@mail.ru
ORCID iD: 0000-0002-8182-5084
SPIN-code: 8626-5394

MD, Dr. Sci. (Medicine), Professor, Chief research associate, Lab. of Invasive Medical Technologies

Russian Federation, Novosibirsk; Novosibirsk

Gennadiy Yu. Yarin

Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences

Email: gennadiyyarin@gmail.com
ORCID iD: 0000-0003-2011-1253
SPIN-code: 7560-2751

MD, Cand. Sci. (Medicine), doctoral student, Lab. of Invasive Medical Technologies

Russian Federation, Novosibirsk

Maxim E. Ryaguzov

Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences

Email: rymax@mail.ru
ORCID iD: 0000-0002-5279-3650

MD, Cand. Sci. (Medicine), research associate, Lab. of Invasive Medical Technologies

Russian Federation, Novosibirsk

Anton Yu. Tsukanov

Omsk State Medical University

Email: autt@mail.ru
ORCID iD: 0000-0002-3497-5856
SPIN-code: 9310-1220
Scopus Author ID: 57194497218

MD, Dr. Sci. (Medicine), Professor, Head, depart. of surgery and urology

Russian Federation, Omsk

Boris V. Sheplev

Novosibirskii mediko-stomatologicheskii institut Dentmaster

Email: shepa@icloud.com
ORCID iD: 0009-0008-4140-3531
SPIN-code: 9905-4138

MD, Dr. Sci. (Medicine), Rector

Russian Federation, Novosibirsk

References

  1. Maria AT, Maumus M, Le Quellec A, et al. Adipose-derived mesenchymal stem cells in autoimmune disorders: state of the art and perspectives for systemic sclerosis. Clin Rev Allergy Immunol. 2017;52(2):234–259. doi: 10.1007/s12016-016-8552-9 EDN: YETLFF
  2. Conklin LS, Hanley PJ, Galipeau J, et al. Intravenous mesenchymal stromal cell therapy for inflammatory bowel disease: Lessons from the acute graft versus host disease experience. Cytotherapy. 2017;19(6):655–667. doi: 10.1016/j.jcyt.2017.03.006
  3. Vigo T, Procaccini C, Ferrara G, et al. IFN-γ orchestrates mesenchymal stem cell plasticity through the signal transducer and activator of transcription 1 and 3 and mammalian target of rapamycin pathways. J Allergy Clin Immunol. 2017;26(8):1667–1676. doi: 10.1016/j.jaci.2016.09.004
  4. Farzamfar S, Garcia LM, Rahmani M, Bolduc S. Navigating the Immunological Crossroads: Mesenchymal Stem/Stromal Cells as Architects of Inflammatory Harmony in Tissue-Engineered Constructs. Bioengineering. 2024;(5):494. doi: 10.3390/bioengineering11050494 EDN: ILUYMK
  5. de Witte SFH, Merino AM, Franquesa M, et al. Cytokine treatment optimises the immunotherapeutic effects of umbilical cord-derived MSC for treatment of inflammatory liver disease. Stem Cell Res Ther. 2017;8(1):140. doi: 10.1186/s13287-017-0590-6 EDN: EXMOYS
  6. Faghih H, Javeri A, Taha MF. Impact of early subcultures on stemness, migration and angiogenic potential of adipose tissue-derived stem cells and their resistance to in vitro ischemic condition. Cytotechnology. 2017;69(6):885–900. doi: 10.1007/s10616-017-0104-5
  7. Yang Q, Huang J, Liu Y, et al. Human Umbilical Cord Mesenchymal Stem Cells Promote Anti-Inflammation and Angiogenesis by Targeting Macrophages in a Rat Uterine Scar Model. Stem Cell Rev Rep. 2024;20(6):1555–1568. doi: 10.1007/s12015-024-10730-6 EDN: YZHSAE
  8. Liu L, Liu H, Chen M, et al. miR-301b~miR-130b-PPARγ axis underlies the adipogenic capacity of mesenchymal stem cells with different tissue origins. Sci Rep. 2017;7(1):1160. doi: 10.1038/s41598-017-01294-2 EDN: BDJURU
  9. Loisel S, Dulong J, Ménard C, et al. Brief report: Proteasomal indoleamine 2,3-dioxygenase degradation reduces the immunosuppressive potential of clinical grade-mesenchymal stromal cells undergoing replicative senescence. Stem Cells. 2017;35:1431–1436. doi: 10.1002/stem.2580
  10. Lopez-Santalla M, Mancheño-Corvo P, Escolano A, et al. Biodistribution and efficacy of human adipose-derived mesenchymal stem cells following intranodal administration in experimental colitis. Front Immunol. 2017;8:638. doi: 10.3389/fimmu.2017.00638
  11. Shree N, Venkategowda S, Venkatranganna MV, Bhonde RR. Treatment with adipose derived mesenchymal stem cells and their conditioned media reverse carrageenan induced paw oedema in db/db mice. Biomed Pharmacother. 2017;90:350–353. doi: 10.1016/j.biopha.2017.03.090
  12. Yang R, Yu T, Zhou Y. Interplay between craniofacial stem cells and immune stimulus. Stem Cell Res Ther. 2017;8(1):147. doi: 10.1186/s13287-017-0607-1 EDN: PEPTMM
  13. Zhang X, Huang W, Chen X, et al. CXCR5-overexpressing mesenchymal stromal cells exhibit enhanced homing and can decrease contact hypersensitivity. Mol Ther. 2017;25(6):1434–1447. doi: 10.1016/j.ymthe.2017.04.004
  14. Zhong Y, Zhu Y, Hu X, et al. Human embryonic stem cell-derived mesenchymal stromal cells suppress inflammation in mouse models of rheumatoid arthritis and lung fibrosis by regulating T-cell function. Cytotherapy. 2024;26(8):930–938. doi: 10.1016/j.jcyt.2024.03.008
  15. Parys M, Kruger JM, Yuzbasiyan-Gurkan V. Evaluation of immunomodulatory properties of feline mesenchymal stem cells. Stem Cells Dev. 2017;26(10):776–785. doi: 10.1089/scd.2016.0041 EDN: YGQJYD
  16. Zhang H, Tao Y, Liu H, et al. Immunomodulatory function of whole human umbilical cord derived mesenchymal stem cells. Mol Immunol. 2017;87):293–299. doi: 10.1016/j.molimm.2017.03.003
  17. Moratin H, Mache I, Goncalves M, et al. Preconditioning with Wound Fluid Enhances Immunosuppressive Properties of Mesenchymal Stromal Cells In Vitro. Int J Mol Sci. 2024;26(1):293. doi: 10.3390/ijms26010293 EDN: QCTGVI
  18. Li CL, Leng Y, Zhao B, et al. Human iPSC-MSC-derived xenografts modulate immune responses by inhibiting the cleavage of caspases. Stem Cells. 2017;35(7):1719–1732. doi: 10.1002/stem.2638
  19. Zhao J, Qi YJ, Wang X, et al. Transforming Growth Factor-β Partially Reversed the Immunosuppressive Effect of Mesenchymal Stem Cells in Mice. Transplant Proc. 2018;50(10):3851–3857. doi: 10.1016/j.transproceed.2018.08.054
  20. Amouzegar A, Mittal SK, Sahu A, et al. Mesenchymal stem cells modulate differentiation of myeloid progenitor cells during inflammation. Stem Cells. 2017;35(6):1532–1541. doi: 10.1002/stem.2611
  21. Jackson MV, Krasnodembskaya AD. Analysis of mitochondrial transfer in direct co-cultures of human monocyte-derived macrophages (MDM) and mesenchymal stem cells (MSC). Bio Protoc. 2017;7(9):e2255. doi: 10.21769/BioProtoc.2255
  22. Xia ZY, Wang Y, Shi N, et al. Fetal mice dermal mesenchymal stem cells promote wound healing by inducing M2 type macrophage polarization. World J Stem Cells. 2025;17(2):101030. doi: 10.4252/wjsc.v17.i2.101030 EDN: KXKEJU
  23. Dong Z, Fu Y, Cai Z, et al. Recent advances in adipose-derived mesenchymal stem cell-derived exosomes for regulating macrophage polarization. Front Immunol. 2025;16:1525466. doi: 10.3389/fimmu.2025.1525466
  24. Tang Y, Li Y, Yang W, et al. Nasal mucosal mesenchymal stem cells promote repair of sciatic nerve injury in rats by modulating the inflammatory microenvironment. Neurosci Lett. 2025;848:138112. doi: 10.1016/j.neulet.2024.138112 EDN: YBRQRR
  25. Ni Y, Tian B, Lv J, et al. 3D-Printed PCL Scaffolds Loaded with bFGF and BMSCs Enhance Tendon-Bone Healing in Rat Rotator Cuff Tears by Immunomodulation and Osteogenesis Promotion. ACS Biomater Sci Eng. 2025;11(2):1123–1139. doi: 10.1021/acsbiomaterials.4c02340 EDN: XGUSJQ
  26. Song J, Huang S, Linghu X, et al. 3D printing of different fibres towards HA/PCL scaffolding induces macrophage polarization and promotes osteogenic differentiation of BMSCs. PLoS One. 2025;20(1):e0314150. doi: 10.1371/journal.pone.0314150 EDN: NJILSE
  27. Yang Q, Wang S, Chen A, et al. A poly(ether-ketone-ketone) composite scaffold simulating the immune-osteogenic cascade for in situ bone regeneration. J Mater Chem B. 2025;13(15):4641-4656. doi: 10.1039/d5tb00070j
  28. Bayati F, Valadi M, Ahmadi A, et al. Evaluation of immunomodulatory effects of co-culture or supernatant of dexamethasone or IFN-γ-treated adipose-derived mesenchymal stem cells on spleen mononuclear cells. Eur Cytokine Netw. 2022;33(3):70–78. doi: 10.1684/ecn.2022.0482 EDN: PEYMGF
  29. de Freitas S, Makiyama EN, Neves BRO, et al. The Influence of Cyanidin-3-Glucoside on the Modulation of Immune Cell Responses by Mesenchymal Stem Cell-Conditioned Medium. Cell Biochem Funct. 2025;43(2):e70059. doi: 10.1002/cbf.70059 EDN: DSOENR
  30. Santos ACA, Sartori T, Borelli P, Fock RA. Prostaglandin F2α in vitro can affect basic inflammatory parameters of mesenchymal stem cells and slight modulating some of their immunomodulatory properties. Prostaglandins Leukot Essent Fatty Acids. 2020;163:102210. doi: 10.1016/j.plefa.2020.102210 EDN: CKPLXL
  31. Kwon HY, Yoon Y, Hong JE, et al. Role of TGF-β and p38 MAPK in TSG-6 Expression in Adipose Tissue-Derived Stem Cells In Vitro and In Vivo. Int J Mol Sci. 2023;25(1):477. doi: 10.3390/ijms25010477 EDN: IWMEOI
  32. Tan Y, Cai J, Wang Z. Epsilon-caprolactone-modified polyethylenimine as a genetic vehicle for stem cell-based bispecific antibody and exosome synergistic therapy. Regen Biomater. 2022;10:rbac090. doi: 10.1093/rb/rbac090 EDN: AHXDQT
  33. Saljoughi Berenji B, Mirershadi F. Molecular Pathways Underlying the Therapeutic Effect of Stem Cells during Asthmatic Changes. Iran J Allergy Asthma Immunol. 2024;23(6):600–624. doi: 10.18502/ijaai.v23i6.17372 EDN: DHMLHK
  34. Colpo GD, Rocha NP, Stimming EF, Teixeira AL. Immunomodulatory strategies for Huntington's disease treatment. CNS Neurol Disord Drug Targets. 2017;16(8):936–944. doi: 10.2174/1871527316666170613084801
  35. Xiao J, Yang R, Biswas S, et al. Neural stem cell-based regenerative approaches for the treatment of multiple sclerosis. Mol Neurobiol. 2018;55(4):3152–3171. doi: 10.1007/s12035-017-0566-7 EDN: YDRDXN
  36. Togha M, Jahanshahi M, Alizadeh L, et al. Rapamycin augments immunomodulatory properties of bone marrow-derived mesenchymal stem cells in experimental autoimmune encephalomyelitis. Mol Neurobiol. 2017;54(4):2445–2457. doi: 10.1007/s12035-016-9840-3 EDN: TKKWYS
  37. Chua AWC, Guo D, Tan JC, et al. Intraperitoneally Delivered Umbilical Cord Lining Mesenchymal Stromal Cells Improve Survival and Kidney Function in Murine Lupus via Myeloid Pathway Targeting. Int J Mol Sci. 2022;24(1):365. doi: 10.3390/ijms24010365 EDN: TRSEOS
  38. Ranjbar A, Hassanzadeh H, Jahandoust F, et al. Allogeneic adipose-derived mesenchymal stromal cell transplantation for refractory lupus nephritis: Results of a phase I clinical trial. Curr Res Transl Med. 2022;70(2):103324. doi: 10.1016/j.retram.2021.103324 EDN: BOHCLK
  39. Feng Z, Yang Y, Liu XZ, et al. Application of cell therapy in rheumatoid Arthritis: Focusing on the immunomodulatory strategies of Mesenchymal stem cells. Int Immunopharmacol. 2025;147:114017. doi: 10.1016/j.intimp.2025.114017 EDN: KGIAAA
  40. Mancheño-Corvo P, Lopez-Santalla M, Menta R, et al. Intralymphatic administration of adipose mesenchymal stem cells reduces the severity of collagen-induced experimental arthritis. Front Immunol. 2017;8:462. doi: 10.3389/fimmu.2017.00462
  41. Sudres M, Maurer M, Robinet M, et al. Preconditioned mesenchymal stem cells treat myasthenia gravis in a humanized preclinical model. JCI Insight. 2017;2(7):89665. doi: 10.1172/jci.insight.89665
  42. Mou L, Wang TB, Wang X, Pu Z. Advancing diabetes treatment: the role of mesenchymal stem cells in islet transplantation. Front Immunol. 2024;15:1389134. doi: 10.3389/fimmu.2024.1389134 EDN: RLLUMK
  43. Goyal P, Malviya R. Stem Cell Therapy for the Management of Type 1 Diabetes: Advances and Perspectives. Endocr Metab Immune Disord Drug Targets. 2023;24(5):549–561. doi: 10.2174/0118715303256582230919093535 EDN: PNFLXU
  44. Mohammadi Ayenehdeh J, Niknam B, Rasouli S, et al. Immunomodulatory and protective effects of adipose tissue-derived mesenchymal stem cells in an allograft islet composite transplantation for experimental autoimmune type 1 diabetes. Immunol Lett. 2017;188:21–31. doi: 10.1016/j.imlet.2017.05.006
  45. Corradi-Perini C, Santos TM, Camara NOS, et al. Co-transplantation of xenogeneic bone marrow-derived mesenchymal stem cells alleviates rejection of pancreatic islets in non-obese diabetic mice. Transplant Proc. 2017;49(4):902–905. doi: 10.1016/j.transproceed.2017.01.064
  46. Qu M, Yuan X, Liu D, et al. Bone marrow-derived mesenchymal stem cells attenuate immune-mediated liver injury and compromise virus control during acute hepatitis b virus infection in mice. Stem Cells Dev. 2017;26(11):818–827. doi: 10.1089/scd.2016.0348
  47. Yang Q, Zhou Y, Farooq W, et al. The immunomodulatory effects of Mesenchymal stem cells on THP-1-derived macrophages against Mycobacterium tuberculosis H37Ra infection. Tuberculosis. 2025;150:102593. doi: 10.1016/j.tube.2024.102593 EDN: HFIZIA
  48. Chang WL, Lee WR, Kuo YC, Huang YH. Vitiligo: An Autoimmune Skin Disease and its Immunomodulatory Therapeutic Intervention. Front Cell Dev Biol. 2021;9:797026. doi: 10.3389/fcell.2021.797026 EDN: ZZBCGG
  49. van den Hoogen P, de Jager SCA, Mol EA, et al. Potential of mesenchymal- and cardiac progenitor cells for therapeutic targeting of B-cells and antibody responses in end-stage heart failure. PLoS One. 2019;14(12):e0227283. doi: 10.1371/journal.pone.0227283 EDN: JFCDDU
  50. Sigaut S, Tardivon C, Jacquens A, et al. Effects of intravascular administration of mesenchymal stromal cells derived from Wharton's Jelly of the umbilical cord on systemic immunomodulation and neuroinflammation after traumatic brain injury (TRAUMACELL): study protocol for a multicentre randomised controlled trial. BMJ Open. 2024;14(12):e091441. doi: 10.1136/bmjopen-2024-091441 EDN: ZRJUTX
  51. Qiu G, Zheng G, Ge M, et al. Adipose-derived mesenchymal stem cells modulate CD14(++)CD16(+) expression on monocytes from sepsis patients in vitro via prostaglandin E2. Stem Cell Res Ther. 2017;8(1):97. doi: 10.1186/s13287-017-0546-x EDN: JUVZFY
  52. Kong T, Seo SK, Han YS, et al. Primed Mesenchymal Stem Cells by IFN-γ and IL-1β Ameliorate Acute Respiratory Distress Syndrome through Enhancing Homing Effect and Immunomodulation. Biomol Ther. 2025;33(2):311–324. doi: 10.4062/biomolther.2025.004 EDN: HMSPDS
  53. Tang XD, Shi L, Monsel A, et al. Mesenchymal stem cell microvesicles attenuate acute lung injury in mice partly mediated by Ang-1 mRNA. Stem Cells. 2017;35(7):1849–1859. doi: 10.1002/stem.2619
  54. Fahlevie F, Apriningsih H, Sutanto YS, et al. Effects of secretome supplementation on interleukin-6, tumor necrosis factor-α, procalcitonin, and the length of stay in acute exacerbation COPD patients. Narra J. 2023;3(2):e171. doi: 10.52225/narra.v3i2.171 EDN: MREMNX
  55. Lettieri S, Bertuccio FR, Del Frate L, et al. The Plastic Interplay between Lung Regeneration Phenomena and Fibrotic Evolution: Current Challenges and Novel Therapeutic Perspectives. Int J Mol Sci. 2023;25(1):547. doi: 10.3390/ijms25010547 EDN: YOOMCQ
  56. Robinson AM, Rahman AA, Miller S, et al. The neuroprotective effects of human bone marrow mesenchymal stem cells are dose-dependent in TNBS colitis. Stem Cell Res Ther. 2017;8(1):87. doi: 10.1186/s13287-017-0540-3 EDN: WCCYTD
  57. Takeyama H, Mizushima T, Uemura M, et al. Adipose-derived stem cells ameliorate experimental murine colitis via tsp-1-dependent activation of latent TGF-β. Dig Dis Sci. 2017;62(8):1963–1974. doi: 10.1007/s10620-017-4578-y EDN: FKRFXY
  58. Maiborodin IV, Morozov VV, Anikeev АА, et al. Macrophage reaction to multipotent mesenchymal stromal cells introduction into surgical trauma site in rats. Novosti Khirurgii. 2017;25(3):233–241. doi: 10.18484/2305-0047.2017.3.233 EDN: YNWXFR
  59. Maiborodin IV, Morozov VV, Matveeva VA, et al. Initial stages of angiogenesis after acute experimental local venous outflow disturbances and application of cell technologies. Bull Exp Biol Med. 2017;163(1):142–147. doi: 10.1007/s10517-017-3755-5 EDN: XMVUEY
  60. Maiborodin I, Lushnikova E, Klinnikova M, Klochkova S. Some Special Aspects of Liver Repair after Resection and Administration of Multipotent Stromal Cells in Experiment. Life. 2021;11(1):66. doi: 10.3390/life11010066 EDN: YPUREY
  61. Arzi B, Clark KC, Sundaram A, et al. Therapeutic efficacy of fresh, allogeneic mesenchymal stem cells for severe refractory feline chronic gingivostomatitis. Stem Cells Transl Med. 2017;6(8):1710–1722. doi: 10.1002/sctm.17-0035
  62. Maiborodin IV, Yakimova NV, Matveyeva VA, et al. Angiogenesis in rat uterine cicatrix after injection of autologous bone marrow mesenchymal stem cells. Bull Exp Biol Med. 2011;150(6):756–761. doi: 10.1007/s10517-011-1242-y EDN: OHRMGN
  63. Maiborodin IV, Onoprienko NV, Chastikin GA. Morphological changes in rat uterine tissues and possibility of spontaneous labor as a result of injection of multipotent mesenchymal stromal cells against the background of hydrometra. Bull Exp Biol Med. 2015;159(4):511–516. doi: 10.1007/s10517-015-3005-7 EDN: WTLZVV
  64. Xin L, Wei C, Tong X, et al. In situ delivery of apoptotic bodies derived from mesenchymal stem cells via a hyaluronic acid hydrogel: A therapy for intrauterine adhesions. Bioact Mater. 2021;12:107–119. doi: 10.1016/j.bioactmat.2021.10.025 EDN: HJORTF
  65. Konenkov VI, Borodin YI, Dergacheva TI, et al. Effects of bone marrow multipotent mesenchymal stromal cells and their secretory products on microcirculation in the broad ligament of the uterus of wistar rats during experimental chronic genital inflammation. Bull Exp Biol Med. 2017;163(1):78–81. doi: 10.1007/s10517-017-3742-x EDN: XNHKPD
  66. Gan L, Duan H, Xu Q, et al. Human amniotic mesenchymal stromal cell transplantation improves endometrial regeneration in rodent models of intrauterine adhesions. Cytotherapy. 2017;19(5):603–616. doi: 10.1016/j.jcyt.2017.02.003
  67. Kota DJ, Prabhakara KS, Toledano-Furman N, et al. Prostaglandin E2 indicates therapeutic efficacy of mesenchymal stem cells in experimental traumatic brain injury. Stem Cells. 2017;35(5):1416–1430. doi: 10.1002/stem.2603
  68. Matveeva D, Kashirina D, Ezdakova M, et al. Senescence-Associated Alterations in Matrisome of Mesenchymal Stem Cells. Int J Mol Sci. 2024;25(10):5332. doi: 10.3390/ijms25105332 EDN: PABPQC
  69. Yin Y, Wu RX, He XT, et al. Influences of age-related changes in mesenchymal stem cells on macrophages during in-vitro culture. Stem Cell Res Ther. 2017;8(1):153. doi: 10.1186/s13287-017-0608-0 EDN: YIJVUX
  70. Abdelhamid L, Hussein H, Ghanem M, Eissa N. Retinoic acid-mediated anti-inflammatory responses in equine immune cells stimulated by LPS and allogeneic mesenchymal stem cells. Res Vet Sci. 2017;114:225–232. doi: 10.1016/j.rvsc.2017.05.006
  71. Bahrami B, Hosseini A, Talei AR, et al. Adipose derived stem cells exert immunomodulatory effects on natural killer cells in breast cancer. Cell J. 2017;19(1):137–145. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC5241510

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

© 2025 Eco-Vector